Radiotracers are small amounts of radioactive material attached to biologically active molecules, designed to travel through the body and emit signals that imaging equipment can detect from the outside. A doctor injects (or has you inhale or swallow) a radiotracer, and its radioactive atoms act like tiny beacons, revealing where the molecule goes, how fast it gets there, and how much of it accumulates in a given tissue. The concept is elegant: by tagging something your body already recognizes with a radioactive label, physicians can watch biological processes unfold in real time without surgery or biopsy. But the details of how radiotracers are built, what makes them safe, and how far their uses extend beyond cancer scans are worth understanding.
The Basic Idea Behind a Radiotracer
Every radiotracer has two functional parts. One is a carrier molecule, something that participates in a normal biological process. It might be a sugar your cells burn for energy, a molecule that binds to a specific receptor on a tumor, or a compound that flows with your blood. The other part is a radioactive atom, called a radionuclide, bonded to or incorporated into that carrier. As the radionuclide decays, it emits radiation, and detectors outside the body pick up those emissions to create an image.
The most widely used radiotracer in the world is FDG, a modified glucose molecule tagged with fluorine-18. Your cells absorb FDG the same way they absorb regular glucose, but once inside, FDG gets stuck. It cannot be fully metabolized, so it accumulates. Cancer cells, which burn glucose at a much higher rate than most normal tissue, light up on the scan. In lung cancer, for instance, virtually all tumors tested express high levels of the glucose transporter that pulls FDG inside the cell, which is a big part of why FDG-PET works so reliably for spotting those tumors.1Journal of Nuclear Medicine. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer
Not all radiotracers work by mimicking sugar, though. Some target specific receptors on cell surfaces. Others flow through the bloodstream to map how well blood reaches a particular organ. The carrier molecule determines where the tracer goes; the radionuclide determines how it is detected.
How Radiotracers Are Made
Producing a radiotracer is a race against the clock. Many of the most useful radionuclides have half-lives measured in minutes or hours, meaning the material loses half its radioactivity in that time. Fluorine-18 has a half-life of about 110 minutes. Technetium-99m, the workhorse of a different imaging technique called SPECT, has a half-life of about six hours. That short lifespan is a feature for patient safety, since the radioactivity fades quickly, but it makes manufacturing and delivery a logistical challenge.
Most short-lived radionuclides for PET imaging are produced in cyclotrons, which are compact particle accelerators. A cyclotron accelerates protons and slams them into a target material, triggering a nuclear reaction that creates the desired radioactive isotope. Small medical cyclotrons with proton energies below 20 MeV handle the bulk of clinical radionuclide production.2PubMed Central. Production of novel diagnostic radionuclides in small medical cyclotrons These machines are compact enough to sit inside a hospital or nearby radiopharmacy, which matters enormously when your product is decaying by the minute.3Radiation Physics and Chemistry. Use of cyclotrons in medicine
Technetium-99m takes a different production route. It is typically extracted from a molybdenum-99 generator, a device sometimes called a “moly cow” that can be shipped to hospitals and milked for fresh technetium as needed. The extraction process is fast; under optimized conditions, roughly 95% of the technetium-99m can be separated in just five to ten minutes.4Journal of Nuclear Medicine Radiology & Radiation Therapy. Radiochemical Technology for Production of Preparations of Technetium – 99m on Extraction Centrifugal Semi-Countercurrent Generator
Facilities that lack an on-site cyclotron must have their PET radiotracers shipped in from outside suppliers. One Canadian PET center documented receiving FDG from a vendor more than 1,000 kilometers away via commercial airline cargo, a supply chain that introduced real reliability problems and required careful calibration to account for decay during transit.5Journal of Nuclear Medicine Technology. Practical Aspects of 18F-FDG PET When Receiving 18F-FDG from a Distant Supplier The short half-lives that make radiotracers safe for patients are the same thing that makes their supply chains fragile.
How Scanners Pick Up the Signal
The two main imaging technologies that use radiotracers are PET and SPECT, and they detect radiation in fundamentally different ways.
In PET, the radionuclide emits a positron, the antimatter counterpart of an electron. Almost immediately, that positron collides with a nearby electron and both are annihilated, producing two high-energy photons that fly off in exactly opposite directions. A ring of detectors surrounding the patient catches both photons nearly simultaneously, and by tracing the line between the two detection points, the scanner pinpoints where the annihilation event occurred.6Zeitschrift für Medizinische Physik. Detectors in positron emission tomography Millions of these coincidence events build up into a three-dimensional map of radiotracer concentration throughout the body.
SPECT works differently. Its radionuclides emit single gamma-ray photons rather than positron-annihilation pairs. Because the scanner cannot rely on coincidence detection, it uses physical collimators, essentially lead plates with holes, to determine the direction each photon came from. The tradeoff is lower sensitivity and somewhat coarser spatial resolution compared with PET. Traditional collimator designs used in clinical SPECT achieve subcentimeter resolution, while specialized pinhole collimators developed for small-animal research can reach below a millimeter.7PubMed Central. Review of SPECT collimator selection, optimization, and fabrication for clinical and preclinical imaging
In practice, most modern scanners combine either PET or SPECT with a CT scan taken at the same session. The CT provides a detailed anatomical picture, while the radiotracer image shows biological activity. Overlaying the two lets a physician see not just that something is metabolically active, but exactly where in the body it sits.
Cancer Imaging and Treatment Planning
Oncology is by far the largest clinical use of radiotracers. PET/CT has become a critical tool in clinical oncology with an expanding role in guiding radiation treatment planning.8Advances in Radiation Oncology. What Are Radiotracers and How Do They Work? When a radiation oncologist needs to aim a beam precisely at a tumor while sparing healthy tissue, knowing where the metabolically active cancer actually lives, rather than just where a mass shows up on a CT, can change the treatment plan considerably.
FDG is the default cancer radiotracer, but it is not the only one. In breast cancer, for example, researchers have developed radiolabeled molecules that target specific receptors on tumor cells, assess the tumor’s local environment, and identify distant metastases.9Translational Oncology. Currents status of radiotracers for breast cancer imaging in PET Going beyond glucose uptake to target specific molecular markers gives oncologists a more detailed picture of the tumor’s biology. PET imaging can reveal information about receptor expression, metabolism, oxygen levels, and tissue density within a tumor, along with how drugs behave once administered.10Nature Reviews Cancer. Advances in PET imaging of cancer
Heart Disease and Brain Disorders
Radiotracers are not just for cancer. Two other major clinical applications stand out: heart imaging and neurological diagnosis.
For heart disease, myocardial perfusion imaging uses radiotracers to measure how well blood flows through the heart muscle. SPECT-based perfusion imaging has been the standard clinical approach for decades, but PET is gaining ground because of better image quality and superior diagnostic accuracy. PET also enables dynamic imaging that can quantify blood flow in absolute units, giving cardiologists a precise measurement rather than a relative comparison.11PubMed. PET and SPECT Tracers for Myocardial Perfusion Imaging A recently FDA-approved fluorine-18 tracer called flurpiridaz adds another option for cardiac PET, one that is also suited to accurate blood-flow measurement.12JACC: Cardiovascular Imaging. Established and Emerging Fluorine-18–Labeled Cardiac PET Radiotracers
In neurology, amyloid PET imaging has transformed the diagnosis of Alzheimer’s disease. Specific radiotracers bind to amyloid plaques, one of the hallmark protein deposits in Alzheimer’s brains, and light them up on a PET scan. This approach has been approved by the FDA, the European Medicines Agency, and other regulatory bodies around the world, giving clinicians a way to detect amyloid buildup while a patient is still alive rather than waiting for autopsy confirmation.13PubMed Central. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review Different tracers target different pathological features. The tracer known as PIB selectively labels amyloid plaques, while another called FDDNP binds to both amyloid plaques and neurofibrillary tangles, a second type of protein aggregate found in Alzheimer’s.14NeuroImage. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer’s disease This distinction matters for research and may eventually help tailor treatment based on which protein pathology dominates in a given patient.
How Safe Is the Radiation Exposure?
A common worry is that injecting radioactive material sounds dangerous. In reality, the doses used in radiotracer imaging are low and drop quickly. The total effective dose from a standard FDG PET/CT procedure is roughly 10 millisieverts. Most of that, about 6 to 7 millisieverts, comes from the radiotracer circulating inside the body, with the CT portion adding another 2 to 4 millisieverts if a low-dose scan is used.15Radiation Protection Dosimetry. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG For context, the average person absorbs about 3 millisieverts per year from natural background radiation, so a PET/CT is roughly equivalent to two to three years of everyday exposure compressed into a single session.
The dose goes up if a full diagnostic-quality CT is performed alongside the PET, so physicians try to avoid redundant CT scans when a recent one already exists. In patients with malignant lymphoma, who may undergo repeated imaging over years of treatment, the cumulative radiation exposure is considered justified but should still be managed carefully, especially in children.16PubMed Central. Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma
Pregnant women should avoid PET/CT unless the scan is essential. For nursing mothers, breastfeeding does not need to be interrupted after a PET/CT, but close contact with a small child should be limited for a few hours after the injection to minimize the child’s exposure.15Radiation Protection Dosimetry. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG Hospital staff protect themselves primarily through distance: the radiation dose drops sharply the farther you stand from the source.
Theranostics and the Diagnosis-to-Treatment Bridge
One of the most interesting developments in nuclear medicine is theranostics, a strategy that uses radiotracers for both diagnosis and therapy by swapping the radionuclide on the same carrier molecule. The idea is straightforward: if a diagnostic radiotracer shows that a tumor expresses a particular receptor, you can replace the imaging radionuclide with a therapeutic one that emits radiation powerful enough to kill those tumor cells.17Seminars in Radiation Oncology. Theranostics: The Role of Quantitative Nuclear Medicine Imaging
This approach has attracted growing attention in oncology because it allows treatment to be guided by the biology of each individual tumor.18PubMed Central. Recent advances in theranostics and oncology PET: emerging radionuclides and targets The diagnostic scan effectively serves as an audition: if the tracer accumulates heavily in the tumor, the therapeutic version should too, and the patient is a good candidate. If the tumor does not take up the tracer, the therapy would not reach its target, and the patient can be spared a treatment unlikely to help. Peptide-based radiopharmaceuticals, for example, have been developed that can both image and treat tumors expressing specific molecular targets.19PubMed Central. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases
Designing these dual-purpose radiotracers is not simple. The carrier molecule must bind tightly to the tumor target and hold onto the radionuclide without letting it leak into healthy tissue. Researchers are now exploring cleavable linkers between the radionuclide and the carrier that would allow controlled, tissue-specific metabolism: the radioactive payload stays locked to the tumor while a stable metabolite clears quickly from organs that would otherwise absorb unwanted dose.20PubMed Central. New tactics in the design of theranostic radiotracers
ImmunoPET and Antibody-Based Tracers
A newer class of radiotracers swaps small molecules for antibodies, the large Y-shaped proteins your immune system uses to recognize threats. ImmunoPET combines the sensitivity of PET with the highly specific targeting ability of monoclonal antibodies, and researchers have used it to image a broad range of molecules on cancer cells and in the surrounding tumor environment.21PubMed Central. ImmunoPET: Antibody-Based PET Imaging in Solid Tumors
One radionuclide that pairs well with antibodies is zirconium-89, which has a half-life of about 3.3 days. That relatively long half-life is important because antibodies are big molecules that circulate in the blood for days before fully accumulating at their target. Early clinical trials using zirconium-89-labeled antibodies showed that tracer uptake on PET correlated with target expression levels measured in tumor biopsies, suggesting the scans genuinely reflect what is happening at the molecular level.22PubMed Central. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? If that link holds up, immunoPET could eventually help predict which patients will respond to a given antibody therapy before they even start treatment.
Total-Body PET Scanners
Conventional PET scanners image a section of the body at a time, typically about 20 to 25 centimeters of axial length per bed position. A full torso scan requires the bed to move the patient through the ring in several steps. A new generation of total-body PET scanners, with detector rings nearly two meters long, can capture the entire body at once. The uEXPLORER, a 194-centimeter-long PET/CT system, was built to do exactly that.23PubMed Central. Subsecond total-body imaging using ultrasensitive positron emission tomography
The practical benefits are substantial. Because the scanner sees the entire body simultaneously, it collects far more of the emitted photons, boosting sensitivity dramatically. That extra sensitivity can be traded for faster scans, lower injected doses, or both. It also enables truly dynamic whole-body imaging: researchers can track a radiotracer’s journey through every organ at the same time, with high temporal resolution, something that was previously impossible when only a slice of the body was in the field of view at any moment.24PubMed Central. Internal dosimetry in F-18 FDG PET examinations based on long-time-measured organ activities using total-body PET/CT For pharmacology research, that capability is transformative: you can watch how a new drug distributes across the entire body in real time.
Radiotracers Outside Medicine
Radiotracers are not confined to hospitals. In hydrology, radioactive tracers have been used for decades to study how water moves through the environment, including measuring stream flow rates, tracking how long it takes for runoff to travel through a watershed, studying lake circulation, and mapping groundwater movement.25The International Journal of Applied Radiation and Isotopes. Tracer techniques in hydrology A small amount of tracer injected upstream can reveal underground flow paths that would be nearly impossible to trace by other means.
Plant scientists have also adopted PET imaging to study how metabolites move through living plants. By labeling carbon, nitrogen, or water with positron-emitting isotopes, researchers can watch nutrient transport in real time with millimeter-scale resolution across an entire plant.26PubMed Central. Exploring the transport of plant metabolites using positron emitting radiotracers The time-dependent data from these experiments feed into models of how plants distribute resources, which has implications for crop science and understanding how plants respond to stress. It is a reminder that the core principle behind radiotracers, tagging something with a detectable label and watching where it goes, applies to any system where you want to track invisible flows, whether that system is a human body, a river, or a soybean plant.